{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:37:20Z","timestamp":1789087040949,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00432-022-04316-3","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T08:02:42Z","timestamp":1661673762000},"page":"3965-3976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects"],"prefix":"10.1007","volume":"149","author":[{"given":"Cynthia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Shatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Okhuysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,28]]},"reference":[{"issue":"10","key":"4316_CR1","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/17474124.2021.1948328","volume":"15","author":"R Alessandro","year":"2021","unstructured":"Alessandro R, Veronica M, Matteo S, Francesco M (2021) Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-SM-TKI combinations: a meta-analysis. Expert Rev Gastroenterol Hepatol 15(10):1225\u20131232. https:\/\/doi.org\/10.1080\/17474124.2021.1948328","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"4316_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3109\/0284186X.2015.1119883","volume":"55","author":"MJ Boers-Sonderen","year":"2016","unstructured":"Boers-Sonderen MJ, Mulder SF, Nagtegaal ID et al (2016) Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa? Acta Oncol 55(4):444\u2013448. https:\/\/doi.org\/10.3109\/0284186X.2015.1119883","journal-title":"Acta Oncol"},{"issue":"2","key":"4316_CR3","first-page":"106","volume":"25","author":"S Boussios","year":"2012","unstructured":"Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N (2012) Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol 25(2):106\u2013118","journal-title":"Ann Gastroenterol"},{"key":"4316_CR4","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S163391","author":"CB Chen","year":"2018","unstructured":"Chen CB, Wu MY, Ng CY et al (2018) Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. https:\/\/doi.org\/10.2147\/CMAR.S163391","journal-title":"Cancer Manag Res"},{"issue":"7","key":"4316_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, Von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472\u2013480. https:\/\/doi.org\/10.1056\/NEJMoa020461","journal-title":"N Engl J Med"},{"issue":"4","key":"4316_CR6","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","volume":"160","author":"M Dougan","year":"2021","unstructured":"Dougan M, Wang Y, Rubio-Tapia A, Lim JK (2021) AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 160(4):1384\u20131393. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.063","journal-title":"Gastroenterology"},{"issue":"29","key":"4316_CR7","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, Muller SP et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639\u20133646. https:\/\/doi.org\/10.1200\/JCO.2012.48.4659","journal-title":"J Clin Oncol"},{"key":"4316_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-319-91442-8_3","volume":"211","author":"T Ettrich","year":"2018","unstructured":"Ettrich T, Seufferlein T (2018) Regorafenib. Recent Resul Cancer Res 211:45\u201356. https:\/\/doi.org\/10.1007\/978-3-319-91442-8_3","journal-title":"Recent Resul Cancer Res"},{"issue":"1","key":"4316_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10637-008-9146-z","volume":"27","author":"TW Flaig","year":"2008","unstructured":"Flaig TW, Kim FJ, La Rosa FG et al (2008) Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 27(1):83\u201387. https:\/\/doi.org\/10.1007\/s10637-008-9146-z","journal-title":"Invest New Drugs"},{"key":"4316_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2012","unstructured":"Grothey A, Cutsem EV, Sobrero A et al (2012) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X","journal-title":"Lancet"},{"issue":"5","key":"4316_CR11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"TJ Hartmann","year":"2009","unstructured":"Hartmann TJ, Haap M, Kopp H, Lipp H (2009) Tyrosine kinase inhibitors\u2014a review on pharmacology, metabolism and side effects. Curr Drug Metabolism Curr Drug Metab 10(5):470\u2013481. https:\/\/doi.org\/10.2174\/138920009788897975","journal-title":"Curr Drug Metabolism Curr Drug Metab"},{"issue":"8","key":"4316_CR12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1200\/JCO.2009.25.4029","volume":"28","author":"EB Haura","year":"2010","unstructured":"Haura EB, Tanvetyanon T, Chiappori A et al (2010) Phase I\/II study of the src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 28(8):1387\u20131394. https:\/\/doi.org\/10.1200\/JCO.2009.25.4029","journal-title":"J Clin Oncol"},{"issue":"39","key":"4316_CR13","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.3748\/wjg.14.6096","volume":"14","author":"H Hur","year":"2008","unstructured":"Hur H, Park AR, Jee SB et al (2008) Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment. World J Gastroenterol 14(39):6096\u20136099. https:\/\/doi.org\/10.3748\/wjg.14.6096","journal-title":"World J Gastroenterol"},{"issue":"12","key":"4316_CR14","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96(12):1788\u20131795. https:\/\/doi.org\/10.1038\/sj.bjc.6603813","journal-title":"Br J Cancer"},{"issue":"4","key":"4316_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/01.cad.0000203385.45163.76","volume":"17","author":"S Kanazawa","year":"2006","unstructured":"Kanazawa S, Yamaguchi K, Kinoshita Y et al (2006) Aspirin reduces adverse effects of gefitinib. Anticancer Drugs 17(4):423\u2013427. https:\/\/doi.org\/10.1097\/01.cad.0000203385.45163.76","journal-title":"Anticancer Drugs"},{"issue":"34","key":"4316_CR16","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","volume":"33","author":"K Kelly","year":"2015","unstructured":"Kelly K, Altorki NK, Eberhardt WEE et al (2015) Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind. Phase III Trial J Clin Oncol 33(34):4007\u20134014. https:\/\/doi.org\/10.1200\/JCO.2015.61.8918","journal-title":"Phase III Trial J Clin Oncol"},{"issue":"9","key":"4316_CR17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","volume":"13","author":"S Leboulleux","year":"2012","unstructured":"Leboulleux S, Bastholt L, Krause T et al (2012) Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 13(9):897\u2013905. https:\/\/doi.org\/10.1016\/S1470-2045(12)70335-2","journal-title":"Lancet Oncol"},{"issue":"10","key":"4316_CR18","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1200\/JCO.2011.36.1709","volume":"30","author":"JS Lee","year":"2012","unstructured":"Lee JS, Hirsh V, Keunchil Q et al (2012) Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30(10):1114\u20131121. https:\/\/doi.org\/10.1200\/JCO.2011.36.1709","journal-title":"J Clin Oncol"},{"key":"4316_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.11.004","volume":"134","author":"K Loay","year":"2019","unstructured":"Loay K, Shohdy KS, Lasheen S et al (2019) Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review. Crit Rev Oncol Hematol 134:56\u201364. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.11.004","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"4316_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/ncponc1087","volume":"5","author":"Y Loriot","year":"2008","unstructured":"Loriot Y, Perlemuter G, Malka D et al (2008) Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Rev Clin Oncol 5(5):268\u2013278. https:\/\/doi.org\/10.1038\/ncponc1087","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"4316_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.clpt.2006.04.007","volume":"80","author":"JF Lu","year":"2006","unstructured":"Lu JF, Eppler SM, Wolf J et al (2006) Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80(2):136\u2013145. https:\/\/doi.org\/10.1016\/j.clpt.2006.04.007","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"4316_CR22","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","volume":"18","author":"M Martin","year":"2017","unstructured":"Martin M, Holmes FA, Ejlertsen B et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688\u20131700. https:\/\/doi.org\/10.1016\/S1470-2045(17)30717-9","journal-title":"Lancet Oncol"},{"issue":"4","key":"4316_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.17305\/bjbms.2008.2905","volume":"8","author":"B Mehik","year":"2008","unstructured":"Mehik B, Stanetic M, Tinjic L, Smoljanovic V (2008) Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB\/IV non-small cell lung cancer. Bosn J Basic Med Sci 8(4):386\u2013390","journal-title":"Bosn J Basic Med Sci"},{"issue":"2","key":"4316_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115\u2013124. https:\/\/doi.org\/10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"issue":"14","key":"4316_CR25","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290","journal-title":"N Engl J Med"},{"issue":"12","key":"4316_CR26","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103\u20131115","journal-title":"N Engl J Med"},{"issue":"14","key":"4316_CR27","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289\u20131300","journal-title":"N Engl J Med"},{"issue":"7","key":"4316_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A et al (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609","journal-title":"N Engl J Med"},{"issue":"8","key":"4316_CR29","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","volume":"29","author":"RB Natale","year":"2011","unstructured":"Natale RB, Thongprasert S, Greco FA et al (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29(8):1059\u20131066. https:\/\/doi.org\/10.1200\/JCO.2010.28.5981","journal-title":"J Clin Oncol"},{"key":"4316_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","volume":"136","author":"S Paydas","year":"2019","unstructured":"Paydas S (2019) Management of adverse effects\/toxicity of ibrutinib. Crit Rev Oncol Hematol 136:56\u201363. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"4316_CR31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl AE, Altman JK, Cortes J et al (2017) Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study. Lancet Oncol 18(8):1061\u20131075. https:\/\/doi.org\/10.1016\/S1470-2045(17)30416-3","journal-title":"Lancet Oncol"},{"issue":"9807","key":"4316_CR32","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(11)61613-9","journal-title":"Lancet"},{"issue":"12","key":"4316_CR33","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116\u20131127","journal-title":"N Engl J Med"},{"key":"4316_CR34","doi-asserted-by":"publisher","first-page":"105463","DOI":"10.1016\/j.phrs.2021.105463","volume":"165","author":"R Roskoski","year":"2021","unstructured":"Roskoski R (2021) Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. Pharmacol Res 165:105463. https:\/\/doi.org\/10.1016\/j.phrs.2021.105463","journal-title":"Pharmacol Res"},{"issue":"1","key":"4316_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10549-018-05102-x","volume":"175","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Di Palma JA et al (2019) The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat 175(1):5\u201315. https:\/\/doi.org\/10.1007\/s10549-018-05102-x","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4316_CR36","first-page":"130","volume":"55","author":"M Saito","year":"2014","unstructured":"Saito M, Izumiyama K, Mori A et al (2014) Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Rinsho Ketsueki 55(1):130\u2013132","journal-title":"Rinsho Ketsueki"},{"issue":"4","key":"4316_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ijc.28544","volume":"135","author":"M Santoni","year":"2014","unstructured":"Santoni M, Conti A, Giorgi UD et al (2014) Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. Int J Cancer 135(4):763\u2013773. https:\/\/doi.org\/10.1002\/ijc.28544","journal-title":"Int J Cancer"},{"issue":"1","key":"4316_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1200\/JCO.2005.04.057","volume":"23","author":"NT Shah","year":"2005","unstructured":"Shah NT, Kris MG, Pao W et al (2005) Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23(1):165\u2013174. https:\/\/doi.org\/10.1200\/JCO.2005.04.057","journal-title":"J Clin Oncol"},{"issue":"1","key":"4316_CR39","first-page":"46","volume":"34","author":"C Shieh","year":"2021","unstructured":"Shieh C, Chalikonda D, Block P, Shinn B, Kistler AC (2021) Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis. Ann Gastroenterol 34(1):46\u201352","journal-title":"Ann Gastroenterol"},{"issue":"4","key":"4316_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","volume":"7","author":"A Som","year":"2019","unstructured":"Som A, Mandaliya R, Alsaadi D et al (2019) Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases. 7(4):405\u2013418","journal-title":"World J Clin Cases."},{"issue":"2","key":"4316_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"4316_CR42","unstructured":"Thomson RJ, Moshirfar M, Ronquillo Y (2021) Tyrosine kinase inhibitors. StatPearls, Orlando, FL. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563322\/. Accessed 10 October 2021."},{"issue":"43","key":"4316_CR43","doi-asserted-by":"publisher","first-page":"26588","DOI":"10.1074\/jbc.271.43.26588","volume":"271","author":"JM Uribe","year":"1996","unstructured":"Uribe JM, Keely SJ, Traynor-Kaplan AE, Barrett KE (1996) Phosphatidylinositol 3-kinase mediates the inhibitory effect of epidermal growth factor on calcium-dependent chloride secretion in T84 human colonic epithelial cells. J Biol Chem 271(43):26588\u201326595. https:\/\/doi.org\/10.1074\/jbc.271.43.26588","journal-title":"J Biol Chem"},{"issue":"14","key":"4316_CR44","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.ejca.2006.03.029","volume":"42","author":"M Van Glabbeke","year":"2006","unstructured":"Van Glabbeke M, Verweij J, Casali PG et al (2006) Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European organisation for research and treatment of cancer, the Italian sarcoma group, and the Australasian gastro-intestinal trials group (EORTC-ISG-AGITG). Eur J Cancer 42(14):2277\u20132285. https:\/\/doi.org\/10.1016\/j.ejca.2006.03.029","journal-title":"Eur J Cancer"},{"issue":"1","key":"4316_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5\u00a0year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):55. https:\/\/doi.org\/10.1186\/s13045-017-0417-z","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4316_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10456-010-9197-6","volume":"14","author":"M Walraven","year":"2011","unstructured":"Walraven M, Witteveen PO, Lolkema MPJ et al (2011) Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 14(2):135\u2013141. https:\/\/doi.org\/10.1007\/s10456-010-9197-6","journal-title":"Angiogenesis"},{"issue":"8","key":"4316_CR47","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/ibd\/izy104","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E et al (2018) Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 24(8):1695\u20131705. https:\/\/doi.org\/10.1093\/ibd\/izy104","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"4316_CR48","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X et al (2017) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18(11):1454\u20131466. https:\/\/doi.org\/10.1016\/S1470-2045(17)30608-3","journal-title":"Lancet Oncol"},{"key":"4316_CR49","doi-asserted-by":"publisher","first-page":"18839","DOI":"10.1016\/j.bbcan.2020.188391","volume":"1874","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang Y, Wang K, Chen L (2020) Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer 1874:18839","journal-title":"Biochim Biophys Acta Rev Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04316-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04316-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04316-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:15:17Z","timestamp":1688213717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04316-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,28]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4316"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04316-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,28]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethics approval for this study was granted by the MD Anderson Institutional Review Board (PA18-0472). Patient consent was waived for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study was granted a waiver of patient consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}